According to an article by 2minutemedicine, the immuno-modulatory drug  T?1 (Zadaxin) led to a decrease in pro-inflammatory markers and an increase in anti-inflammatory markers in a murine study of cystic fibrosis.

In CF cells and mice, treatment with T?1 increased CFTR expression at the plasma membrane through reducing endosomal targeting. This increase in cell surface expression was accompanied by an increase in activity of the protein, demonstrating potential pulmonary function improvement following treatment with T?1, 2minutemedicine reported.

Publishing in Nature Medicine, study authors concluded: “T?1 displayed two combined properties that favorably opposed CF symptomatology: it reduced inflammation and increased CFTR maturation, stability and activity. By virtue of this two-pronged action, T?1 has strong potential to be an efficacious single-molecule-based therapeutic agent for CF.”